MIRM News and Press, Mirum Pharmaceuticals Inc. From 02/09/23

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the SVB Securities Global Biopharma Confe...

Summary Albireo, Mirum Pharmaceuticals, Inc.'s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. The biggest value driver of Mirum is Livmarli, currently the only approved life-saving product in a rare pediatric disease market worth $500 mill...

- $76 million in total revenue and $74 million net product sales anticipated for LIVMARLI for 2022, preliminary and unaudited - sNDA for LIVMARLI in PFIC submission planned for first quarter 2023 - Multiple data analyses planned in 2023 advancing late-stage cholestasis programs Mi...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the annual J.P. Morgan Healthcare Conference ...

Summary ALBO has one approved indication and one more filed for a label expansion. The company has begun a slow revenue stream and has decent cash. A small opportunity presents itself in the company's measured but steady growth. For further details see: Alb...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Lon Cardon, Ph.D., FMedSci, to its Board of Directors where he will also serve as a member of the Nominating and Governance Committee. Dr. Cardon brings nearly 30 years of extensive industry and academic experience in d...

- First and only medication approved in both the U.S. and Europe to treat cholestatic pruritus in patients with Alagille syndrome. - Approval supported by more than six years of LIVMARLI data demonstrating improvements in transplant-free survival, serum bile acids, growth, xanthomas, and qual...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the decision to discontinue the OHANA study of volixibat in intrahepatic cholestasis of pregnancy (ICP) due to enrollment feasibility. ICP is a setting of cholestasis during pregnancy with pruritus and elevated bile acid levels...

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2022 Results Conference Call November 09, 2022 08:00 AM ET Company Participants Ian Clements - CFO Chris Peetz - President, CEO & Director Peter Radovich - COO Pamela Vig - Head of R&D Richard Thompson - Profe...

Mirum Pharmaceuticals press release ( NASDAQ: MIRM ): Q3 GAAP EPS of -$1.02 beats by $0.05 . Revenue of $18.78M (+275.6% Y/Y) misses by $2.03M . As of September 30, 2022, Mirum had cash, cash equivalents, restricted cash equivalents and investments of $285.3M. ...